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plants, fungi, and bacteria and exhibit a wide range ofNovel Mechanism for Priming
biological activities of interest to the pharmaceuticalAromatic Polyketide Synthases industry (antibiotics, anticancer, antifungals, or immu-
nosuppressive agents) and the agrochemical industry
(insecticides or antiparasitic agents) [3]. From simply
looking at the chemical structures of polyketides, thereIn this issue of Chemistry & Biology, a novel priming
are no common structural features to suggest that thesemechanism is proposed for aromatic polyketide bio-
compounds all belong to the same family. However,synthesis, with an iterative type I polyketide synthase
when the various biosynthetic pathways for generatinggenerating a starter unit primed for a type II polyketide
polyketide are considered, it is clear that they share asynthase [6]. This novel priming system participates
common thread: all polyketide biosynthesis involves thein hedamycin biosynthesis, a DNA alkylating agent.
assembly of carbon chains from acyl precursors in a
series of reactions catalyzed by a complex enzymaticMany natural products are bioactive, and polyketides
system, the polyketide synthase (PKS). The reaction be-constitute one of the most important families of natural
products [1, 2]. Polyketides are widely distributed in gins when PKS is primed by a starter molecule and then
Previews
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continues with repetitive decarboxylative condensation
of CoA analogs of simple carboxylic acids.
Based on their protein architecture, PKSs have been
classified into three distinct families (type I, type II, and
type III), but increasing evidence supports the view that
PKSs have much greater diversity [4]. Type I PKSs, the
modular PKSs, are large multifunctional polypeptides;
examples are the erythromycin, rapamycin, or avermec-
tin PKSs. Type II PKSs are multienzyme complexes of
single proteins and usually work as iterative heterodi-
mers resembling type II fatty acid synthases from bacte-
ria and plants; the actinorhodin, tetracenomycin C, and
granaticin are classical examples of this subfamily. Fi-
nally, a more recently discovered subfamily in bacteria,
the type III PKSs, are iterative homodimers; a type III
PKs is involved in the biosynthesis of the diffusible red-
brown pigment produced by the erythromycin producer.
Aromatic polyketides are usually synthesized by type
II PKSs. In most cases, biosynthesis of bacterial aro-
matic polyketides is initiated by priming acetate as
starter unit, but some aromatic PKSs can also use other
starter units such as benzoate, salicylate, malonamate,
or short-chain fatty acids [5]. Although the mechanism Figure 1. Structure of Hedamycin
of attachment of starter units is not well understood,
Red, hexenoate starter unit; blue, aromatic polyketide moiety; green,
one can speculate that activation and transfer of these deoxysugars.
nonacetate starter units is mediated by CoA ligases or
a ketosynthase (KSIII) and an acyltransferase. Iterative usage of a type I PKS (here to synthesize the
In the July issue of Chemistry & Biology, Jon Thorson starter unit) goes against the dogma for these multido-
and colleagues [6] report an alternative priming system main enzyme complexes. However, over the past few
for the biosynthesis of an aromatic polyketide. The plur- years, evidence has accumulated to support the iterative
amycin family of antitumor antibiotics was first discov- use of single modules of type I PKSs. This process,
ered more than 50 years ago by Umezawa and coworkers known as “stuttering,” occurs with some PKSs as an
and was found to have antimicrobial and anticancer activ- aberrant process producing low levels of side products
ity [7]. For many years, pluramycins remained chemical [9, 10], but some type I PKSs have probably evolved to
evolutionary oddities composed of chemical features repeatedly use some modules during polyketide chain
borrowed from diverse groups of natural products. extension as a programmed event [11–15]. Conse-
These antibiotics are structurally complex DNA-reactive quently, there is great interest in the Thorson groups’
agents consisting of a planar 4-H-anthra(1,2-b)pyran observation of an iterative type I PKS initiating biosyn-
chromophore with either carbohydrate or epoxide moie- thesis of the polyketide chain. Their report provides the
ties attached at the corner of the planar chromophores, first description of this novel mechanism, which uses a
depending on the pluramycin type. The pluramycin fam- type I PKS acting iteratively for the generation of the
ily has the ability to intercalate into the DNA molecule starter unit that subsequently primes the type II PKS
and interact with both grooves of the DNA helix. Further- system.
more, those pluramycins displaying epoxides also have Another notable structural peculiarity of hedamycin is
the ability to cause DNA alkylation [8]. the C-glycosidic attachment of two different sugars to
Thorson and colleagues isolated and characterized the aglycon. The glycosyltransferases responsible for
the first biosynthetic gene cluster for a pluramycin-type the sugar transfer have been identified within the heda-
compound, hedamycin (Figure 1). A region of approxi- mycin cluster. Most bioactive compounds are glycosy-
mately 45 kb from the chromosome of the hedamycin lated through O-glycosidic linkages; C-glycosidation is
producer Streptomyces griseoruber ATCC15422 was found less frequently in natural products. The unique
cloned and sequenced, and 32 open reading frames regio- and stereoselectivity of the two identified heda-
were identified, many of which the authors suggest have mycin glycosyltransferases make them especially good
a role in hedamycin biosynthesis. Sequence analysis of candidates for engineering novel C-glycosides through
the gene cluster showed the presence of the classical combinatorial biosynthesis.
type II PKS components: a KS-KS heterodimer and
an ACP but also a second catalytic ketosynthase (KSIII) Jose´ A. Salas
and an AT, usually an indication of nonacetate priming Departamento de Biologia Funcional e Instituto
in PKSs. Two genes were also found that encode mod- Universitario de Oncologı´a del Principado
ules of a type I PKS. The authors propose that one of de Asturias (I.U.O.P.A)
these genes (HedT) could act as a loading domain, while Universidad de Oviedo
the other (HedU) could act iteratively to elongate one 33006 Oviedo
acetyl-CoA starter unit with two malonyl-CoA extender Spain
units, thus synthesizing the unusual hexenoate starter
until after several ketoreduction and dehydration steps.
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Last year, a group from Sirna Therapeutics reportedRibozyme Diagnostics
the development of a target activated ribozyme capableComes of Age of detecting zeptomole (1021M) quantities of hepatitis
C viral RNA in solution [9]. The key to such sensitive
detection properties is that the ribozyme component
parts have absolutely no activity in the absence of theBiosensing ribozymes could soon be used to diagnose
cognate substrate, which differs from previously pub-viral infection. The Kossen group from Sirna Therapeu-
lished allosteric ribozymes whose rates of activity aretics have developed a sensitive, high-throughput
dictated by the rate differences of ribozyme function
means of screening for hepatitis C virus, using their
in the absence and presence of substrate or allosteric
target activated half-ribozyme technology, as reported
modifier. The Sirna group developed a “half-ribozyme”
in the June issue of Chemistry & Biology [1].
approach in which the target RNA itself serves to com-
plete the ribozyme structure. In this ribozyme reaction
A little over two decades ago, the first demonstrations scheme, the multiple turnover class 1 ligase motif devel-
of catalytic RNAs (ribozymes) were reported in the litera- oped by Bartel and colleagues [10] was truncated to
ture [2, 3]. These ribozymes were the cleavage-ligation form a bimolecular substrate RNA, which interacts with
catalyzing Tetrahymena ribosomal RNA intron [3] and the target sequence to allow ligation of one of the sub-
the RNA component of the endoribonuclease RNase strate RNAs containing a 3 cis-diol with a 5 triphos-
P, which catalyzes the site-specific cleavage of the 5 phate containing substrate RNA oligo (Figure 1). This
precursor segment of transfer RNAs [2]. Subsequent to half-ribozyme has no ligase activity in the absence of
these important findings, several other smaller, naturally target RNA and displayed an observed rate increase of
occurring ribozymes with RNA cleavage and ligation 4,000,000-fold when bound to the target.
activities have been described [4], and most recently This exquisitely sensitive ribozyme reporter has been
the RNA component of the large ribosomal subunit has further analyzed for detection of HCV sequences and
been identified as the ribosomal transpeptidase [5]. The high-throughput assays, as reported in last month’s
spectrum of the catalytic capabilities of RNA was greatly Chemistry & Biology by Kossen and coworkers [1]. In this
enhanced following the development of techniques for study, naturally occurring variants of HCV that contain
in vitro evolution of RNAs with new capabilities ranging mismatched pairings to the half-ribozyme were analyzed
from ATP hydrolysis to polymer biosynthesis [6]. An for their effects on ribozyme-mediated ligation of the sub-
important development for evolving biologically and strate RNAs. By extending the base pairing of the ribo-
chemically useful ribozyme functions is the addition of zyme to target the mismatched sequences, these were
allosteric activation functions to ribozymes, which can accommodated without significant kinetic impairment
be mediated by binding of a variety of ligands ranging of target-dependent ligation rates. The variant HCV se-
from small organic molecules through proteins or nu- quences represent greater than 80% of the GenBank
cleic acid oligomers [7, 8]. Allosteric activation is the HCV 5UTR entries, with one of the sequences repre-
key to generating biosensing nucleic acids that can be senting 66%. Thus, the half-ribozyme assay can be gen-
used to monitor any of a number of biological or chemi- erally applied to the majority of HCV clinical samples.
cal processes. Ribo-reporters could in essence become In order to make this assay suitable for clinical appli-
inexpensive replacements for antibodies and other cations, the Sirna investigators collaborated with inves-
tigators from Thermo Electron, Corp., Point of Care andmethods currently in use for diagnostic testing.
